Clinical Trials Browser

Phase 3 × INDUSTRY × Hormone-Refractory Prostate Cancer × Clear all

NCT01133704 2010-09-08

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Phase 3 Completed

98 enrolled 9 charts

Hormone-Refractory Prostate Cancer